At the same time, it can activate ERK1/2 and Akt and up-regulate the expression of cyclin D1, cyclin E1, cyclin A2, and cyclin B1, while the ERK1/2 inhibitor and PI3K inhibitor could significantly reduce the LIPUS-induced phosphorylation of ERK1/2 and Akt and inhibit the LIPUS-induced proliferation of AD-MSCs. Here, AKT1 is linked to Alzheimer disease.